Matinas (MTNB): Highbridge files 13G/A reporting 0% ownership
Matinas BioPharma (MTNB): ownership update — Highbridge Capital Management, LLC filed Amendment No. 2 to Schedule 13G reporting 0% beneficial ownership of Matinas BioPharma common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Matinas BioPharma (MTNB): ownership update — Highbridge Capital Management, LLC filed Amendment No. 2 to Schedule 13G reporting 0% beneficial ownership of Matinas BioPharma common stock. The filing shows 0 shares beneficially owned with 0 sole or shared voting and dispositive power.
The date of event triggering the filing is 09/30/2025. Highbridge certifies the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Highbridge report in its Schedule 13G/A for MTNB?
Who is the reporting person in this MTNB 13G/A?
What is the event date associated with this MTNB filing?
How much voting power did Highbridge report for MTNB?
What class of securities does the MTNB filing cover?
What certification did Highbridge include in the MTNB 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.